Normal human epithelial cells in culture have generally shown a limited proliferative potential of f10 to 40 population doublings before encountering a stress-associated senescence barrier (stasis) associated with elevated levels of cyclindependent kinase inhibitors p16 and/or p21. We now show that simple changes in medium composition can expand the proliferative potential of human mammary epithelial cells (HMEC) initiated as primary cultures to 50 to 60 population doublings followed by p16-positive, senescence-associated B-galactosidase-positive stasis. We compared the properties of growing and senescent pre-stasis HMEC with growing and senescent post-selection HMEC, that is, cells grown in a serum-free medium that overcame stasis via silencing of p16 expression and that display senescence associated with telomere dysfunction. Cultured pre-stasis populations contained cells expressing markers associated with luminal and myoepithelial HMEC lineages in vivo in contrast to the basal-like phenotype of the post-selection HMEC. Gene transcript and protein expression, DNA damage-associated markers, mean telomere restriction fragment length, and genomic stability differed significantly between HMEC populations at the stasis versus telomere dysfunction senescence barriers. Senescent isogenic fibroblasts showed greater similarity to HMEC at stasis than at telomere dysfunction, although their gene transcript profile was distinct from HMEC at both senescence barriers. These studies support our model of the senescence barriers encountered by cultured HMEC in which the first barrier, stasis, is retinoblastoma-mediated and independent of telomere length, whereas a second barrier (agonescence or crisis) results from telomere attrition leading to telomere dysfunction. Additionally, the ability to maintain long-term growth of genomically stable multilineage pre-stasis HMEC populations can greatly enhance experimentation with normal HMEC.

PTEN, a protein tyrosine phosphatase with homology to tensin, is a tumor-suppressor gene on chromosome 10q23. Somatic mutations in PTEN occur in multiple tumors, most markedly glioblastomas. Germ-line mutations in PTEN are responsible for Cowden disease (CD), a rare autosomal dominant multiple-hamartoma syndrome. PTEN was sequenced from constitutional DNA from 25 families. Germ-line PTEN mutations were detected in all of five families with both breast cancer and CD, in one family with juvenile polyposis syndrome, and in one of four families with breast and thyroid tumors. In this last case, signs of CD were subtle and were diagnosed only in the context of mutation analysis. PTEN mutations were not detected in 13 families at high risk of breast and/or ovarian cancer. No PTEN-coding-sequence polymorphisms were detected in 70 independent chromosomes. Seven PTEN germ-line mutations occurred, five nonsense and two missense mutations, in six of nine PTEN exons. The wild-type PTEN allele was lost from renal, uterine, breast, and thyroid tumors from a single patient. Loss of PTEN expression was an early event, reflected in loss of the wild-type allele in DNA from normal tissue adjacent to the breast and thyroid tumors. In RNA from normal tissues from three families, mutant transcripts appeared unstable. Germ-line PTEN mutations predispose to breast cancer in association with CD, although the signs of CD may be subtle.

No abstract

mac25, the subject of this report, was selected by the differential display of mRNA method in a search for genes overexpressed in senescent human mammary epithelial cells. mac25 had previously been cloned as a discrete gene, preferentially expressed in normal, leptomeningial cells compared with meningioma tumors. mac25 is another member of the insulin growth factor-binding protein (IGFBP)

The MYC oncoprotein is a transcription factor that coordinates cell growth and division. MYC overexpression exacerbates genomic instability and sensitizes cells to apoptotic stimuli. Here we demonstrate that MYC directly stimulates transcription of the human Werner syndrome gene, WRN, which encodes a conserved RecQ helicase. Loss-of-function mutations in WRN lead to genomic instability, an elevated cancer risk, and premature cellular senescence. The overexpression of MYC in WRN syndrome fibroblasts or after WRN depletion from control fibroblasts led to rapid cellular senescence that could not be suppressed by hTERT expression. We propose that WRN up-regulation by MYC may promote MYC-driven tumorigenesis by preventing cellular senescence.Supplemental material is available at http://parma.fhcrc.org/ CGrandori. Alterations in c-myc oncogene expression have been implicated in the pathogenesis of several human cancers, including Burkitt and diffuse large B-cell lymphomas, breast and prostate cancer, colon cancer, melanoma, and multiple myeloma (Nesbit et al. 1999). The MYC oncoprotein is a basic helix-loop-helix-leucine zipper (bHLHZIP) transcription factor that through dimerization with MAX protein binds to specific DNA elements ("E boxes") and modulates transcription of a wide variety of genes (for review, see Dang 1999;Grandori et al. 2000;Oster et al. 2002). The proteins encoded by MYC transcriptional target genes appear to regulate cell-cycle progression and cell growth while sensitizing cells to apoptotic stimuli (Evan et al. 1992). MYC may also be able to promote tumorigenesis by up-regulating the expression of genes such as hTERT that play a role in cellular immortalization or the escape from senescence (Wang et al. 1998a;Greenberg et al. 1999;Wu et al. 1999). We reasoned that MYC might modulate the expression of other genes that control cellular senescence, and thus determined whether the gene encoding the Werner syndrome RecQ helicase protein is a MYC transcriptional target.Werner syndrome (WRN) is an uncommon, autosomal recessive genetic instability syndrome that results from loss-of-function mutations in the chromosome 8p12-p11.2 WRN gene (Yu et al. 1996). The WRN phenotype resembles premature aging, and includes genomic instability, an elevated risk of malignancy, and accelerated cellular senescence. Genetic instability following loss of the 162-kD WRN RecQ helicase protein reflects the physiologic role of WRN in mitotic recombination and repair (Brosh and Bohr 2002;Saintigny et al. 2002). Conversely, the elevated levels of WRN observed in immortalized and human tumor cell lines may help insure continuous cell proliferation (Shiratori et al. 1999). In order to delineate potential interactions between MYC and WRN in tumorigenesis, we determined whether WRN expression is modulated by MYC, and monitored cellular responses to MYC overexpression in the absence of WRN. The results indicated that WRN expression appears to be required to avoid cellular senescence upon MYC up-regulation in hTERT-immortalized fibr...

A cDNA clone, designated CaN19 (originally called clone 19), isolated by subtractive hybridization, contains sequences that are preferentially expressed in normal mammary epithelial cells but not in breast tumor cells. Comparison of its deduced amino acid sequence with sequences in the GenBank data base revealed similarity with the S100 protein family, a group of small Ca(2+)-binding modulator proteins involved in cell cycle progression and cell differentiation. CaN19 expression is down-regulated in normal cells by A23187, a calcium ionophore, suggesting that its regulation is calcium-dependent. We have assigned CaN19 to human chromosome 1q21-q24, a region containing four other S100-related genes. In contrast to CaN19 mRNA expression, most members of the S100 protein family are activated or overexpressed in tumor cells. Synchronization experiments by growth-factor deprivation demonstrated a biphasic induction of CaN19 expression in normal cells, approximately 2-fold in early G1 phase and another 2- to 3-fold at the G1/S boundary. Exposure of mammary tumor cells to 5-aza-2'-deoxycytidine, an inhibitor of DNA methylation, reactivated the expression of CaN19 mRNA.

Human claudin-1 is an integral protein component of tight junctions, a structure controlling cell-to-cell adhesion and, consequently, regulating paracellular and transcellular transport of solutes across human epithelia and endothelia. Recently, a claudin-1 (CLDN1) cDNA has been isolated from human mammary epithelial cells (HMECs). CLDN1 expression in HMECs, in contrast to low or undetectable levels of expression in a number of breast tumors and breast cancer cell lines, points to CLDN1 as a possible tumor-suppressor gene. In order to evaluate the CLDN-1 gene in sporadic and hereditary breast cancer, we have characterized its genomic organization and have screened the four coding exons for somatic mutations in 96 sporadic breast carcinomas and for germline mutations in 93 breast cancer patients with a strong family history of breast cancer. In addition, we have compared the 5'-upstream sequences of the human and murine CLDN1 genes to identify putative promoter sequences and have examined both the promoter and coding regions of the human gene in the breast cancer cell lines showing decreased CLDN1 expression. In the sporadic tumors and hereditary breast cancer patients, we have found no evidence to support the involvement of aberrant CLDN1 in breast tumorigenesis. Likewise, in the breast cancer cell lines, no genetic alterations in the promoter or coding sequences have been identified that would explain the loss of CLDN1 expression. Other regulatory or epigenetic factors may be involved in the down-regulation of this gene during breast cancer development.

Solid tumor development is complex and encompasses alterations in a variety of physiologic processes such as enhanced proliferative capacity, resistance toward apoptosis, metastatic potential and escape from immunologic detection. However, beside these diverse and multiple changes occurring in tumors, cellular accessibility of nutrients and growth factors must be present continuously. To ensure early neoplastic survival, the onset of neovascularization is one of the most significant hallmarks during tumor progression. 1,2 One rate-limiting step of growing tumors may be the diffusion of molecules into the paracellular space. Therefore, it has been hypothesized that the presence of intact functional tight junctions (TJs) in tumors of epithelial origin might limit the optimal supply of biomolecules necessary for cell growth and survival. 3,4 In fact, several reports provide evidence for the relevance of functional loss of TJs in developing human tumors in vivo. Diminished TJ formation has been reported for hepatocellular carcinoma, 5 thyroid tumors 6 and colon carcinoma. 7 In experimental animal models, alterations of TJs have been observed in canine bladder carcinoma 8 and murine mammary carcinoma. 9 Furthermore, the loss of TJ-associated molecules such as ZO-1 has been correlated with tumor progression. 10,11 Finally, the relevance of TJ complexes in tumorigenesis is highlighted by the fact that loss of TJ-associated tumor suppressor genes also results in tumor formation in imaginal disks of Drosophila. 12,13 TJs constitute the barrier of paracellular flux in epithelia and control the permeation of molecules between the apical lumen and basolateral face. Identification of the multiple proteins that constitute the epithelia-or tissue-specific TJs have only recently been elucidated. 14 -19 One of the first molecules associated with the TJ, occludin, was identified as a requisite integral protein. 20 However, in the murine occludin knockout TJ-like structures were still present. The 4-transmembrane proteins claudin-1 and -2 were then shown to reconstitute the TJ. 21 It has been suggested that claudin-1 and -2 might recruit occludin to TJs, 22 and both claudins have been shown to interact with intracellular TJ-associated proteins from the membrane-associated guanylate kinase (MAGUK) family. Sequence and similarity analysis have revealed the existence of a claudin family with up to more than 20 proteins, 15,17,23 but for only a few members of the claudin family has a specialized function been identified. 24 -30 In parallel with the identification of the murine claudin-1 and -2, we identified the human counterpart of the murine claudin-1, previously called SEMP1, in a differential display approach comparing isogenic exponentially growing, nontumorigenic and senescent human epithelial breast cells. 26 The human claudin-1 (CLDN1), which shares a 98% amino acid homology to the murine claudin-1, is expressed in many human tissues containing epithelium, such as mammary gland. Of particular interest in this regard is that...